article thumbnail

Skeletal Muscle Pathology in Pulmonary Arterial Hypertension and Its Contribution to Exercise Intolerance

Journal of the American Heart Association

Pulmonary arterial hypertension is a disease of the pulmonary vasculature, resulting in elevated pressure in the pulmonary arteries and disrupting the physiological coordination between the right heart and the pulmonary circulation. Journal of the American Heart Association, Ahead of Print.

article thumbnail

Comparative hemodynamic responses to upright and recumbent cycling in patients with exercise intolerance

Frontiers in Cardiovascular Medicine

Hemodynamic variables were measured at rest and across various exercise intensities.ResultsSignificant differences were observed in right atrial pressure (RAP), mean pulmonary artery pressure (mPAP), and pulmonary artery wedge pressure (PAWP) between upright and recumbent positions.

article thumbnail

Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension

Med Page Today

(MedPage Today) -- The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday. A novel activin signaling inhibitor, sotatercept is indicated to increase exercise capacity.

Pulmonary 140
article thumbnail

The effect of individual exercise rehabilitation program on ischemic burden and cardiac function in patients with ischemic non-obstructive coronary heart disease: a randomized parallel controlled clinical trial

Frontiers in Cardiovascular Medicine

The control group underwent a standard rehabilitation program, while the intervention group participated in an individualized exercise rehabilitation program. This program was tailored to each patient, with a 50% power intensity exercise prescription derived from the results of the patient's Cardiopulmonary Exercise Testing (CPET) evaluation.

article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Cardiopulmonary Exercise Test Interpretation Across the Lifespan in Congenital Heart Disease: A Scientific Statement From the American Heart Association

Journal of the American Heart Association

Cardiopulmonary exercise testing is a valuable tool for assessing functional capacity, evaluating cardiac and pulmonary pathology, and providing guidance on prognosis and interventional recommendations. This is an updated report of the American Heart Association's previous publications on exercise in children.

article thumbnail

Non‐invasive prediction of pulmonary vascular disease‐related exercise intolerance and survival in non‐group 1 pulmonary hypertension

European Journal of Heart Failure

Aims The clinical utility of pulmonary hypertension (PH) risk scores in non-group 1 PH with pulmonary vascular disease (PVD) remains unresolved. Exercise right heart catheterization reserve, ventricular interdependence and right ventricularpulmonary artery (RV-PA) coupling were compared across risk categories.